Metformin monotherapy
Metformin monotherapy has been studied in 1 paper since 2024: 1 observational study in people. The newest paper, Dec 21, 2024: “Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight”.
1 paper studies it1 findingUpdated
See all 1 papers on metformin monotherapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“T2D patients on metformin monotherapy exhibited enriched purine, glutathione and sphingolipid metabolism”
Humans: a single group. Cells, worms or flies and mice: nothing yet.
- 1 lab in 1 country
- Funders: CH Foundation and 1 more
- Humans1
What did studies of metformin monotherapy find?
1Studies of metformin monotherapy measured one outcome, purine metabolism.
Purine metabolism
upin humans1
1 study
Purine metabolism
upin humans1
Metformin monotherapy is linked with higher purine metabolism in humans.
“T2D patients on metformin monotherapy exhibited enriched purine, glutathione and sphingolipid metabolism”
Humansserum
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Latest
Biomedicine & Pharmacotherapy
Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight
Cohort study in peopleMild cognitive impairment